ClinicalTrials.gg
Enrolling by invitationNCT07778069Updated Oct 20, 2026

VR for Steroid Joint Injections - Feasibility

An interventional study of VR-PAT in Acute Pain, Procedural Anxiety and Juvenile Idiopahtic Arthritis, sponsored by Nationwide Children's Hospital. Enrolling by invitation at 1 site in United States. Open to participants aged 5 Years to 17 Years. Per ClinicalTrials.gov, last updated 2026-10-20.

Sponsored by Nationwide Children's Hospital · Not applicable, Interventional, and Treatment

Updated Oct 20, 2026Start date movedGo to Updates ↓
Phase
Not applicable
Study type
Interventional
Enrollment
10
Allocation
Not applicable
Ages
5 Years to 17 Years
Sex
All
01

Study summary

The goal of the project is to implement virtual reality for pain and anxiety management for patients undergoing intra-articular glucocorticoid injections in the outpatient pediatric rheumatology clinic.

Read the detailed description

To assess feasibility of VR use in the clinic, 10 patients will be recruited to use VR during non-sedated intra-articular (IA) glucocorticoid injections. All patients will be offered our typical analgesia (LMX topical cream, freeze spray, lidocaine injection). Patients and caregivers will be asked to fill out pre-injection and post-injection surveys, and staff (rheumatology clinic nurses) will be asked for feedback regarding feasibility of VR in clinical workflows.

The specific aims of the study are to:

Aim 1: Assess the feasibility and efficacy of VR use to reduce pain in patients undergoing non-sedated IA glucocorticoid injections at Nationwide Children's Hospital

02

Conditions studied

  • Acute Pain
  • Procedural Anxiety
  • Juvenile Idiopahtic Arthritis

Browse trials for

Keywords

  • Virtual Reality
  • VR
  • JIA
  • Rheumatology
03

In context

Acute Pain

1,073 studies on the registry are indexed under Acute Pain; 166 are open to participants now.

This study's planned enrollment of 10 is below the median of 86 across 902 interventional studies indexed under Acute Pain.

Browse Acute Pain studies →

Lead sponsor

Nationwide Children's Hospital is the lead sponsor of 233 studies on the registry; 43 are open to participants now.

Of its 17 completed or terminated interventional studies of FDA-regulated products, 9 (53%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
5 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. rheumatology patients (5-17 years old) who are undergoing an IA injection in the Nationwide Children's Rheumatology Clinic,
  2. have a legal guardian present for patients less than 18 years old for the procedure (for ), and
  3. can communicate orally.

Exclusion criteria

Exclusion Criteria:

  1. any wounds that may interfere with study procedures,
  2. vision, hearing, or cognitive/motor impairments preventing valid administration of study measures,
  3. history of motion sickness, seizure disorder, dizziness, or migraine headaches precipitated by visual auras,
  4. minors in foster care,
  5. unable to communicate in English,
  6. pregnant women, or
  7. prisoners
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
10 participants (estimated)

Study arms

  • Experimental
    Intervention

    Participants will be using the VR-PAT during IA glucocorticoid injections

    Other: VR-PAT

Interventions

  • OtherVR-PAT

    Virtual Reality Pain Alleviation Therapeutic (VR-PAT) via a Pico Neo3 Pro Eye

06

What researchers measure

Primary outcomes

  1. Practicality/utility of the VR experience as a pain and anxiety management tool for IA joint injection procedures

    Assessed by the nurse answering the following questions: "Is this distraction tool helpful during joint injection procedures (Yes/No)?" and "Is this distraction tool easy to use during joint injections (Yes/No)?"

    Time frame: Immediately following the IA joint injection procedure

Secondary outcomes

  1. Self-reported change procedural anxiety

    0-10 Numerical Rating Scale (NRS) (self-reported), 0(min)-10(max), with higher score indicating worse anxiety.

    Time frame: Immediately before the IA joint injection procedure and immediately after

  2. Self-reported pain

    0-10 Numerical Rating Scale (NRS) (self-reported), 0(min)-10(max), with higher score indicating worse pain. Asked for worst pain, average pain, and time spent thinking about pain.

    Time frame: Immediately following the IA joint injection procedure

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2026 (actual). Primary completion is estimated for Jul 2029, 33 months after the start.

Of 424 non-industry interventional studies with no phase under Acute Pain, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 23. This study's planned 33 months is above that.

Counting every sponsor, half of 430 studies reached it within 11 months; a quarter within 5 and three quarters within 23.

Start moved once since we started tracking on Sep 25, 2026: Aug 2026 → Oct 2026, on Oct 20, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Aug 17, 2026
First posted
Aug 21, 2026
StartActual
Oct 8, 2026was Aug 2026
Primary completionEst.
Jul 2029
CompletionEst.
Dec 2029
Last update
Oct 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Aug 20, 2026→Oct 8, 2026 (actual)
Oct 20, 2026
Show all 1 update
  1. Oct 20, 2026
    Start date Aug 20, 2026→Oct 8, 2026 (now actual)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07778069
Responsible party
Henry Xiang (Professor of Medicine and Center Director, Nationwide Children's Hospital) — Principal investigator
First posted
Aug 21, 2026
Start date
Oct 8, 2026
Primary completion
Jul 2029 (estimated)
Completion
Dec 2029 (estimated)
Last update
Oct 20, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion